As we move towards the final quarter of the year, global biopharma companies have already raised an incredible $50 billion from public and private financing deals, which represents twice the amount raised for the whole of last year. The cash continues to flow particularly from public offerings. According to a report released by Renaissance Capital the U.S. IPO market as a whole is on track for its busiest year since 2014, with offerings predicted to come thick and fast post Labor Day.